Connection

Miguel Abboud to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Back to Details
This is a "connection" page, showing publications Miguel Abboud has written about Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Miguel Abboud
Connection Strength
0.393
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  1. Delayed initiation of front-line imatinib therapy predicts for poor response to nilotinib as second-line treatment of imatinib-resistant or intolerant CML: single center report of the ENACT trial in Lebanon. Int J Hematol. 2012 Oct; 96(4):521-4.
    View in: PubMed
    Score: 0.393
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.